Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine at ≤ 50 years of age (ICHD-II, 2004 Section 1)~* History of migraine ≥ 12 months with~  * ≤ 14 headache days of which at least 4 have to be migraine days (migraine days count as headache days) in each 28 day period in the 3 months prior to screening~ * During the 28 days following the screening visit, the subject experiences ≤ 14 headache days of which at least 4 have to be migraine days (migraine days count as headache days) as recorded in the eDiary~* No use of any botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck 4 months prior to screening and during the 28 day period prior to randomization~* Headache eDiary was completed on at least 25 of the 28 days prior to randomization~Exclusion Criteria:~* Confounding pain syndromes, e.g. fibromyalgia, complex regional pain syndrome or any pain syndrome that requires regular analgesia~* Psychiatric conditions that are uncontrolled and untreated, including conditions that are not controlled for a minimum of 6 months prior to screening~* History or diagnosis of complicated migraine (ICHD- II, 2004 Section 1), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, migraine with brainstem aura, sporadic and familial hemiplegic migraine~* Unable to differentiate migraine from other headaches~* Have any clinically significant concurrent medical condition~* Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial)~* Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ALD403 Dose Level 1 (Type: EXPERIMENTAL): ALD403 Dose Level 1 (IV)
- ALD403 Dose Level 2 (Type: EXPERIMENTAL): ALD403 Dose Level 2 (IV)
- ALD403 Dose Level 3 (Type: EXPERIMENTAL): ALD403 Dose Level 3 (IV)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).